Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 5/20 | 0.36 |
| ▸ | TOP2A | P11388 | 6/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.33 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19603994 | 1.00 | ADK (0.36) | ADKTOP2APRMT5METTL3SLC29A1 | |
| SCHEMBL19603991 | 0.92 | ADK (0.37) | ADKPRMT5METTL3SLC29A1 | |
| SCHEMBL10178108 | 0.85 | TOP2A (0.32) | TOP2A | |
| SCHEMBL24128139 | 0.85 | TOP2A (0.32) | TOP2A | |
| SCHEMBL19603979 | 0.84 | ADK (0.36) | ADKTOP2APRMT5METTL3SLC29A1 | |
| SCHEMBL10178599 | 0.84 | ADK (0.36) | ADKTOP2APRMT5METTL3SLC29A1 | |
| SCHEMBL19603993 | 0.84 | ADK (0.47) | ADKTOP2APRMT5METTL3SLC29A1 | |
| SCHEMBL10178145 | 0.84 | ADK (0.47) | ADKTOP2APRMT5METTL3SLC29A1 | |
| SCHEMBL10178238 | 0.84 | ADK (0.35) | ADKTOP2APRMT5METTL3SLC29A1 | |
| SCHEMBL16728040 | 0.83 | ADK (0.34) | ADKPRMT5METTL3SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148503-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | UNG, NT5C2, NT5E | ADK 201/4885TOP2A 117/4885PRMT5 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.